Physician profile
Mohamed Farhat
NPI 1104082809
$1,397.80
in general payments reported to CMS, 2019-2025
26 companies · $20.60 in 2025
The $20.60 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $11.41 · 2021: $170 · 2022: $656 · 2023: $524 · 2024: $15.17 · 2025: $20.60.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $469 · Education: $90.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $469.21 |
| Education | $90.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $184.09 | 2021-2023 | Keytruda, Lynparza |
| Glaxosmithkline, LLC. | $145.17 | 2021-2022 | |
| Genzyme Corporation | $117.44 | 2022-2023 | |
| Amgen INC. | $87.66 | 2022-2023 | Lumakras |
| Novartis Pharmaceuticals Corporation | $80.04 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $73.73 | 2020-2023 | Opdivo |
| Sobi, INC | $69.99 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $66.04 | 2022-2023 | Lynparza, Enhertu |
| Celgene Corporation | $63.33 | 2022-2023 | Reblozyl |
| Gilead Sciences, INC. | $56.40 | 2021-2022 | |
| Janssen Biotech, INC. | $52.18 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $49.10 | 2023 | Libtayo |
| Seagen INC. | $41.08 | 2022-2023 | Tukysa |
| Mirati Therapeutics, INC. | $36.90 | 2023 | Krazati |
| Kite Pharma, INC. | $29.75 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $28.32 | 2023 | |
| Beigene USA, INC. | $27.11 | 2023 | Brukinsa |
| Daiichi Sankyo INC. | $26.94 | 2023 | Enhertu |
| Rigel Pharmaceuticals, INC. | $23.33 | 2022 | |
| Adc Therapeutics America, INC. | $22.99 | 2022 | |
| Astellas Pharma US INC | $22.83 | 2022 | |
| Genentech USA, INC. | $22.02 | 2022 | |
| Tolmar Pharmaceuticals, INC. | $21.82 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.67 | 2022 | |
| Abbvie INC. | $16.70 | 2023 | |
| Tempus Ai, INC | $15.17 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohamed Farhat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.